Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide and Semaglutide in Routine Care: 12-Month Weight in All of Us

In All of Us records, year-one weight loss averaged 5.9% with semaglutide and 13.0% with tirzepatide among people with measurements.

Editorial profile: Neil SandersBuy This GLP Editorial Team3 min read
Mean weight change at 12 months, routine US caretirzepatide−13%semaglutide−5.9%the older three−4%14,046 people. The trials report far larger numbers.

When comparing weight loss across GLP-1 trials with routine care, check who had a follow-up weight. In this study, year-one measurements were sparse, especially for tirzepatide [1].

What the All of Us study measured

The cohort included 14,046 adults with obesity starting one of five drugs. The year-one analysis used recorded weights within 45 days of day 365 [1].

That window included 1,476 of 5,656 semaglutide starters (26.1%). Fewer than 20 of 386 tirzepatide starters had a weight in the window. The study reported a mean loss of 5.9% for semaglutide and 13.0% for tirzepatide.

Why the missing weights matter

Participants with a recorded weight may differ from those without one. The comparison used medical records without randomly assigning a drug. Differences in patients, treatment or follow-up could affect the estimates.

Access can affect whether a treatment plan is practical. In our knownwell review, the available visit formats illustrate one practical access consideration. The All of Us study did not compare providers or visit formats.

The researchers also estimated how quickly people reached 15% weight loss. Compared with liraglutide, adjusted hazard ratios were 1.77 for semaglutide and 5.57 for tirzepatide [1]. A hazard ratio measures relative rates over time.

Frequently asked

How many participants had a year-one weight?
For semaglutide, 1,476 of 5,656 had a recorded weight near one year. For tirzepatide, fewer than 20 of 386 did.
Why are these estimates different from those in trials?
Routine care differs from a trial in its patient population, treatment and follow-up. This study cannot isolate those effects.

Sources

  1. [1] Hwang I, Lee SW, Kim Y (2026). Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study Drug Design, Development and Therapy. PMID 42518911

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence